Cornerstone Pharmaceuticals' CPI-613 Phase I Hematologic Malignancies Trial Data Published in AACR's Clinical Cancer …

CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that data from the Phase I clinical trial evaluating CPI-613 …

View original post here:
Cornerstone Pharmaceuticals' CPI-613 Phase I Hematologic Malignancies Trial Data Published in AACR's Clinical Cancer …

Cornerstone Pharmaceuticals Clinical Data on CPI-613 to be Presented at ASCO 2014

CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that data from a Phase I clinical trial of its proprietary first-in-class …

Follow this link:
Cornerstone Pharmaceuticals Clinical Data on CPI-613 to be Presented at ASCO 2014

Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 for the Treatment of Small Cell …

CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a pilot Phase II clinical trial of CPI-613 …

Read more here:
Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 for the Treatment of Small Cell …